孟鲁司特防治早产儿支气管肺发育不良的研究进展  

The role of montelukast in the prevention and treatment of bronchopulmonary dysplasia in premature infants

作　　者：陈霞(综述) 贝斐(审校)[1] Chen Xia;Bei Fei(Department of Neonatology,National Children′s Medical Center/Shanghai Children′s Medical Center,School of Medcine,Shanghai Jiaotong University,Shanghai 200127,China)

机构地区：[1]国家儿童医学中心上海交通大学医学院附属上海儿童医学中心新生儿科,200127

出　　处：《国际儿科学杂志》2021年第9期619-622,共4页International Journal of Pediatrics

摘　　要：支气管肺发育不良是早产儿特别是极低出生体重儿最常见的慢性呼吸系统疾病之一,其中肺发育不成熟、炎症损伤、氧化应激及损伤后异常修复是关键因素。白三烯是5-脂氧合酶途径的促炎介质,参与支气管肺发育不良的发生。孟鲁司特作为白三烯受体拮抗剂,通过抗炎、抗氧化及抗纤维化等作用可能在支气管肺发育不良治疗中起到一定作用。该文将综述孟鲁司特在支气管肺发育不良中应用的潜在作用机制及相关临床研究进展。Bronchopulmonary dysplasia is one of the most common chronic respiratory diseases in premature infants,especially in very low birth weight infants.Lung immaturity,inflammatory injury,oxidative stress and abnormal repair after injury are the important factors.Leukotriene is an inflammatory mediator of 5-lipoxygenase pathway and participates in the occurrence of bronchopulmonary dysplasia.Montelukast,as a leukotriene receptor antagonist,may play a role in the treatment of bronchopulmonary dysplasia through anti-inflammation,anti-oxidation and anti-fibrosis.This article will review the potential mechanism and related clinical researches of montelukast which is used in treating bronchopulmonary dysplasia.

关 键 词：早产儿 支气管肺发育不良 孟鲁司特 白三烯受体拮抗剂 

分 类 号：R722.6[医药卫生—儿科]